Palvella Therapeutics (PVLA) Asset Utilization Ratio (2014 - 2024)
Palvella Therapeutics' (PVLA) quarterly Asset Utilization Ratio came in at 0.12 in Q3 2024, down 121.23% year-on-year from 0.57 in Q4 2023, and down 119.6% on a QoQ basis from 0.61 in Q2 2024.
Palvella Therapeutics (PVLA) Asset Utilization Ratio (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 11 years of Asset Utilization Ratio data on file, last reported at 0.12 in Q3 2024.
- On a quarterly basis, Asset Utilization Ratio fell 121.23% year-over-year to 0.12 in Q3 2024; TTM through Sep 2024 was 0.12, a 121.23% decrease from a year earlier, with the FY2023 full-year figure at 0.75, up 21509.05% from the prior year.
- Asset Utilization Ratio for Q3 2024 stood at 0.12, down from 0.61 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for PVLA reached as high as 1.99 in Q1 2024 and fell as low as 0.12 in Q3 2024.
- Historically, Asset Utilization Ratio has averaged 0.38 across 5 years, with a median of 0.21 in 2021.
- On a YoY basis, Asset Utilization Ratio climbed as much as 6606.14% in 2024 and fell as far as 121.23% in 2024.
- Year by year, Asset Utilization Ratio stood at 0.21 in 2020, then slipped by 21.53% to 0.17 in 2021, then fell by 27.77% to 0.12 in 2022, then surged by 871.4% to 1.16 in 2023, then sank by 110.4% to 0.12 in 2024.
- Per Business Quant data, the three most recent Asset Utilization Ratio figures were 0.12 in Q3 2024, 0.61 in Q2 2024, and 1.99 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -0.12 |
| Jun 30, 2024 | 0.61 |
| Mar 31, 2024 | 1.99 |
| Dec 31, 2023 | 1.16 |
| Sep 30, 2023 | 0.57 |
| Jun 30, 2023 | 0.26 |
| Mar 31, 2023 | 0.03 |
| Dec 31, 2022 | 0.12 |
| Sep 30, 2022 | 0.19 |
| Jun 30, 2022 | 0.19 |
| Mar 31, 2022 | 0.17 |
| Dec 31, 2021 | 0.17 |
| Sep 30, 2021 | 0.09 |
| Jun 30, 2021 | 0.09 |
| Mar 31, 2021 | 0.21 |
| Dec 31, 2020 | 0.21 |
| Sep 30, 2020 | 0.38 |
| Jun 30, 2020 | 0.47 |
| Mar 31, 2020 | 0.39 |
| Dec 31, 2019 | 0.36 |